Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
Classical BCR-ABL-negative myeloproliferative neoplasms (MPNs) are a clonal expansion of myeloid precursors caused by somatic stem cells. Although driver mutations were observed in most MPN patients, the potential clonal disorder remains unclear. We analyzed a total of 1004 newly diagnosed MPN patie...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332500172X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849334813437198336 |
|---|---|
| author | Xiaodong Guo Wenbo Jia Xinyu Yang Hexiao Jia Hanyang Wu Yihong Wei Can Can Na He Hailei Zhang Wancheng Liu Shuang Yu Daoxin Ma |
| author_facet | Xiaodong Guo Wenbo Jia Xinyu Yang Hexiao Jia Hanyang Wu Yihong Wei Can Can Na He Hailei Zhang Wancheng Liu Shuang Yu Daoxin Ma |
| author_sort | Xiaodong Guo |
| collection | DOAJ |
| description | Classical BCR-ABL-negative myeloproliferative neoplasms (MPNs) are a clonal expansion of myeloid precursors caused by somatic stem cells. Although driver mutations were observed in most MPN patients, the potential clonal disorder remains unclear. We analyzed a total of 1004 newly diagnosed MPN patients and next-generation sequencing was performed on the genomic DNA. Primary myelofibrosis (PMF) patients carried the highest LDH level, splenomegaly, and the lowest hemoglobin content. Myeloproliferative Neoplasm, unclassifiable (MPN-U) patients had higher platelet count and frequency of thrombotic events. The top five most frequently mutations were JAK2, ASXL1, TET2, CALR, and DNMT3A. The JAK2 mutation burden was positively correlated with leukocyte counts in all subgroups. PMF patients tend to have more somatic mutations than other patients. Among triple-negative (TN) MPN patients, SH2B3 and SRSF2 were positively correlated, and the NPM1 mutation rate was significantly increased. As for survival, we found that patients with PMF, MPN10 symptoms, JAK2 wild-type, or TN mutation were positively associated with shorter overall survival. The U2AF1 mutation was an independent risk factor for death in MPN patients, and ZRSR2, NF1, and PPM1D mutations were found in patients who progress to AML or MDS. In addition, we created a prediction nomogram by using five variables, which enhanced the precision of estimating survival in MPN patients. Our data provide a novel perspective for the diagnosis, clonal evolution and prognosis of MPNs. |
| format | Article |
| id | doaj-art-db87e25e8fdc4e31a1dbf5a12c583c0d |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-db87e25e8fdc4e31a1dbf5a12c583c0d2025-08-20T03:45:28ZengElsevierTranslational Oncology1936-52332025-08-015810244110.1016/j.tranon.2025.102441Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasmsXiaodong Guo0Wenbo Jia1Xinyu Yang2Hexiao Jia3Hanyang Wu4Yihong Wei5Can Can6Na He7Hailei Zhang8Wancheng Liu9Shuang Yu10Daoxin Ma11Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China; Department of Hematology, Affiliated Hospital of Shandong University of traditional Chinese Medicine, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, ChinaDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China; Corresponding authors at: Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China.Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China; Corresponding authors at: Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China.Classical BCR-ABL-negative myeloproliferative neoplasms (MPNs) are a clonal expansion of myeloid precursors caused by somatic stem cells. Although driver mutations were observed in most MPN patients, the potential clonal disorder remains unclear. We analyzed a total of 1004 newly diagnosed MPN patients and next-generation sequencing was performed on the genomic DNA. Primary myelofibrosis (PMF) patients carried the highest LDH level, splenomegaly, and the lowest hemoglobin content. Myeloproliferative Neoplasm, unclassifiable (MPN-U) patients had higher platelet count and frequency of thrombotic events. The top five most frequently mutations were JAK2, ASXL1, TET2, CALR, and DNMT3A. The JAK2 mutation burden was positively correlated with leukocyte counts in all subgroups. PMF patients tend to have more somatic mutations than other patients. Among triple-negative (TN) MPN patients, SH2B3 and SRSF2 were positively correlated, and the NPM1 mutation rate was significantly increased. As for survival, we found that patients with PMF, MPN10 symptoms, JAK2 wild-type, or TN mutation were positively associated with shorter overall survival. The U2AF1 mutation was an independent risk factor for death in MPN patients, and ZRSR2, NF1, and PPM1D mutations were found in patients who progress to AML or MDS. In addition, we created a prediction nomogram by using five variables, which enhanced the precision of estimating survival in MPN patients. Our data provide a novel perspective for the diagnosis, clonal evolution and prognosis of MPNs.http://www.sciencedirect.com/science/article/pii/S193652332500172XMyeloproliferative neoplasmsClonal evolutionRuxolitinibSomatic mutationsOverall survival |
| spellingShingle | Xiaodong Guo Wenbo Jia Xinyu Yang Hexiao Jia Hanyang Wu Yihong Wei Can Can Na He Hailei Zhang Wancheng Liu Shuang Yu Daoxin Ma Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms Translational Oncology Myeloproliferative neoplasms Clonal evolution Ruxolitinib Somatic mutations Overall survival |
| title | Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms |
| title_full | Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms |
| title_fullStr | Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms |
| title_full_unstemmed | Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms |
| title_short | Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms |
| title_sort | genomic profile helps to predict the clonal evolution and outcome of bcr abl negative myeloproliferative neoplasms |
| topic | Myeloproliferative neoplasms Clonal evolution Ruxolitinib Somatic mutations Overall survival |
| url | http://www.sciencedirect.com/science/article/pii/S193652332500172X |
| work_keys_str_mv | AT xiaodongguo genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT wenbojia genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT xinyuyang genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT hexiaojia genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT hanyangwu genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT yihongwei genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT cancan genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT nahe genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT haileizhang genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT wanchengliu genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT shuangyu genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms AT daoxinma genomicprofilehelpstopredicttheclonalevolutionandoutcomeofbcrablnegativemyeloproliferativeneoplasms |